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Abstract
Background: Information leaflets have been shown to significantly improve awareness of the symptoms of
gynaecological cancers and to reduce perceived barriers to seeking medical help. This record-based, parallel,
randomised control trial study aimed to assess whether receipt of a leaflet would change the behaviour of women
experiencing symptoms indicative of gynaecological cancers by prompting them to visit their general practitioner (GP).
Methods: 15,538 women aged 40 years or over registered with five general practices in Northamptonshire, UK were
randomised to two groups using the SystmOne randomise facility. Those in the intervention group received an
educational leaflet from their general practice explaining the symptoms of gynaecological cancers and advising
symptomatic women to visit their GP. The control group were not contacted. Electronic records were interrogated to
extract sociodemographic data and details of GP consultations for symptoms, tests, referrals and diagnoses relating to
gynaecological cancers in the 4-month period following the mail-out of the leaflets.
Results: 7739 records were extracted from the intervention group and 7799 from the control group. 231 (3.0%) of the
women in the intervention group, and 207 (2.7%) of the controls, presented to their GP with a relevant symptom
during the 4-month period following leaflet distribution. The slightly higher rate in the intervention group did not
reach statistical significance at the 5% level (RR = 1.11; 95% CI 0.92–1.33; z = 1.08; p = 0.28). There was a significantly
lower mean time to first presentation in the symptomatic intervention group (57.2 days, sd = 36.5) compared to the
control group (65.2 days, sd = 35.0) (t = − 2.415; p = 0.016). Survival analysis did not reveal a difference between the
patterns of presentation in the two cohorts (Log Rank (Mantel-Cox) χ2 = 1.42; p = 0.23).
Conclusion: There was no difference between intervention and control groups in the proportion of women
presenting with symptoms identified in the leaflet in the four months following leaflet distribution, although the
women who had been sent a leaflet presented earlier than those in the control group. A larger study is needed to test
for a modest effect of leaflet distribution.
Trial registration: Listed on the ISRCTN registry with study ID ISRCTN61738692 on 23–8-2017 (retrospectively registered).
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Background
Gynaecological cancers (carcinomas of the ovary, cervix,
uterus, vagina, vulva or endometrium) have a combined
UK incidence second only to breast cancer [1]. Earlier
diagnosis of gynaecological cancers is a key strategy in
closing the survival gap between England and the Euro-
pean average [2]. Studies suggest that a main cause of
the delay in diagnosis is deferral in presentation [3–5]
which is thought to be driven in part by low symptom
awareness [6, 7]. Symptoms are often attributed to be-
nign causes [8], and medical help is not sought. The
GP-patient relationship is also influential in
decision-making: almost half the respondents to a survey
using the Cancer Awareness Measure expressed worry
about ‘wasting the doctor’s time’, causing delays [9].
Leaflets can increase cancer awareness and knowledge
[10–12]. However, few studies have examined whether
increased awareness translates into changes in patient
behaviour. There is evidence to suggest that information
leaflets can increase attendance at screening [13] and re-
duce stroke delay [14]. Research here remains limited;
no empirical research confirms that leaflets can promote
symptom presentation to primary care clinicians.
An information leaflet detailing the symptoms of gy-
naecological cancers and encouraging women to present
to their general practitioner with any concerns was de-
veloped using focus groups with experts, cancer survi-
vors and the public [15]. It was tested with the public
and shown to have at least a short-term impact; expos-
ure to the leaflet reduced women’s perceived barriers to
help-seeking, increased symptom knowledge and re-
duced anticipated time to help-seeking [12].
This study aimed to investigate whether being sent this
leaflet affects the rate and timing of presentation to primary
care for symptoms indicative of gynaecological cancers.
Methods
Participants and setting
The research was conducted in five general practices
across Northamptonshire, UK, chosen to include a range
of socio-geographical factors and practice sizes. All prac-
tices used the SystmOne electronic patient record sys-
tem. Registered female patients were eligible for
inclusion if they were 40 years or over (the age group in
whom the majority of gynaecological cancers occur) and
were not on the oncology and palliative care, learning
difficulties or mental health registers.
Sampling
Participants for the control and intervention (leaflet)
groups were selected at random, without replacement,
using the random selection facility within SystmOne from
those women meeting the selection criteria. Approxi-
mately equal proportions of women were selected from
each practice population, with equal numbers of control
and intervention group participants. Those in each group
were flagged using project-specific Read codes.
Intervention
The leaflet was developed by Morris et al. (2016) [12]
through an iterative process involving experts, gynaeco-
logical cancer survivors and the public. It introduces the
gynaecological cancers, listing their symptoms, together
with a check-list for women to record any symptoms
they have had. It concludes with a ‘call to action’ for
women to make a GP appointment if they have any of
the symptoms. The leaflet can be found as a supplemen-
tary file to Morris et al. (2016) [12].
The leaflet was mailed to the home address of each pa-
tient selected for the intervention arm in June 2014,
along with a covering letter from their GP which intro-
duced the research project and included the sentence “I
hope it [the leaflet] will inform you about an important
health message: gynaecological symptoms should be
taken seriously at every age, and discussed with your
doctor if they don’t go away”.
Outcomes
The primary outcome is the period prevalence rate for
women over 40 presenting with relevant signs and
symptoms within four months following distribution.
We estimated the time to presentation up to four
months following leaflet distribution for women seen
with relevant signs and symptoms. We also calculated
the proportion of women over 40 who were subse-
quently referred urgently for specialist assessment to-
gether with the time to urgent referral and noted
gynaecological cancer diagnoses recorded during the
study period, for descriptive analysis only.
Sample size
Previous research from surveys completed using Com-
puter Assisted Personal Interviewing (CAPI) [16] indi-
cates that 44% of women in the general population had
symptoms indicative of gynaecological symptoms in the
previous 3 months. Of these, 30% had seen their GP
about these symptoms. For a power of 95% of detecting
a 13% increase in the attendance rate of symptomatic
women seeing their GP (from 30 to 34%), 3532 symp-
tomatic women are required in each group (α = 0.05).
This effect size was considered to be clinically signifi-
cant. As symptomatic women can be assumed to be 44%
of the total sample group size, this required 8027 women
to be selected for each of the two groups.
Data extraction
A SystmOne query was constructed using a list of over
200 Read codes which included all relevant codes relating
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to the symptoms in the leaflet (130 codes), diagnostic tests
ordered, test results and referrals relating to gynaeco-
logical symptoms and possible gynaecological cancer diag-
noses, together with demographic information.
Patients were identified by a unique, non-identifiable
project number before data was extracted for a four
month period, starting the day after the mail-out date
for the leaflet for each practice. Read codes were
grouped under higher order categories reflecting either
the leaflet content (e.g. in relation to groups of symp-
toms) or meaningful clinical groupings that allow for
variation in codes used between different GPs.
Ethnicity recording in general practice is known to be
problematic [17]. 44.6% (6926) of patients did not have
their ethnicity recorded and, where it was, 91 different
Read codes were used from 4 different code hierarchies.
Only 4.8% of ethnicity records used the recommended
9S codes which map onto principal census categories.
Comparison of ethnicities was therefore not attempted.
The GeoConvert utility [18] was used to map partici-
pant postcode districts against the Lower Layer Super
Output Areas (LSOAs) within that district, together with
the proportion of the district formed by each LSOA.
This information was then used together with the Index
of Multiple Deprivation (IMD) data for each LSOA [19]
to calculate the weighted mean IMD score for each dis-
trict, as a marker of area-level deprivation.
Statistical analysis
Age and IMD score were examined using descriptive sta-
tistics. The sample characteristics of the control and inter-
vention arm were compared using Mann-Whitney tests.
For the primary outcome, a positive outcome was de-
fined as at least one eligible symptom Read code event
recorded for the patient within the four-month study
period. Cochrane’s z-tests were used to investigate differ-
ences in the proportions of women with positive out-
comes in the two groups. Cochrane’s z-test was also
used for comparison of urgent referral rates.
Independent t-tests were used (following confirmation
of normality) for comparison of time to presentation and
referral (there is no censored data for these outcomes).
Comparison of time from date of leaflet distribution to
symptom presentation was subsequently investigated
using Kaplan-Meier survival analysis. The start time for
the event (recorded symptom) for both groups was the
leaflet distribution date for the intervention group. This
start date was therefore treated as a random date for the
control group. This approach assumes that the presenta-
tion rate (per 4 month period) for the control group
would be independent of when that time period began;
the analysis investigates whether there is a difference in
the distribution of presentations between the two
groups. The number of days for those not having a
recorded symptom by the record extraction date was
censored at 4 months (123 days).
All statistical analyses were performed using two-tailed
tests with statistical significance taken at the 5% level.
Results
7739 records were extracted from the 8029 originally
identified as the intervention group and 7799 were ex-
tracted from the 8029 flagged as controls. This discrep-
ancy is likely to be due to records becoming unavailable
(e.g. because of moving from the practice or death) in the
time between initial group identification and data extrac-
tion. The CONSORT flow diagram is shown in Fig. 1.
The data is available from the Zenodo repository [20].
Participant characteristics
There was no difference between groups as assessed by
age or IMD at baseline (see Table 1).
Outcomes data
Of the 7739 women in the leaflet (intervention) group,
231 had relevant symptoms recorded by their GP in the
four-month period following the leaflet distribution
(3.0%). For the 7799 women in the control group, 207
had symptoms recorded in that period (2.7%). Although
there is a slightly higher rate in the intervention group,
this does not reach statistical significance at the 5% level
(RR = 1.11; 95% CI 0.92–1.33; z = 1.08; p = 0.28).
The number of days from the date of the leaflet distri-
bution to the date of the first presentation for a symp-
tom indicative of a gynaecological cancer was calculated
to investigate whether receipt of the leaflet may have an
effect on the delay in symptom reporting by women. For
those presenting with a relevant symptom, the mean
time to presentation (from the leaflet distribution date)
for the control group was 65.2 days (sd = 35.0 days). The
intervention group mean time to presentation was nearly
8 days shorter (57.2 days; sd = 36.5 days). This difference
was statistically significant (t = − 2.415, df = 474, p = 0.016).
These results are shown in Table 2.
Figure 2 shows the survival functions for the women
in the intervention and control arms.
There was an approximately constant presentation rate
over the 4-month period for the control group, whereas
the intervention group showed a higher rate of presenta-
tions in the 20 days following leaflet distribution, after
which the rate was approximately the same as for the
control group. This difference did not reach statistical
significance (Log Rank (Mantel-Cox) χ2 = 1.42, p = 0.23).
In the intervention group, 0.8% of the women (n = 66)
were urgently referred compared to 0.7% of the women
in the control group (n = 51). This difference did not
reach statistical significance at the 5% level (RR = 1.28;
95% CI 0.89–1.85; z = 1.35; p = 0.18).
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The number of days from leaflet distribution to the date
of any urgent referral was calculated and compared be-
tween the intervention and control groups. The means
were 67.7 days (sd = 36.9 days) for the control group and
57.1 days (sd = 37.1 days) for the intervention group. Al-
though this showed a 10-day reduction in the mean time
to urgent referral for the intervention group, it did not
reach statistical significance (t = − 1.53, df = 114, p = 0.13).
Three gynaecological cancers were recorded as being
diagnosed within the study period (four months follow-
ing leaflet distribution): two in intervention group
patients, and one in the control group.
Discussion
Summary
This study is one of the first of its kind to use a rando-
mised controlled trial to quantify the impact of an educa-
tional leaflet on rates of, and time to, presentation for
possible cancer symptoms in primary care. The differences
in rate of gynaecological symptom presentation between
intervention and control group were in the direction
expected, but not statistically significant (3.0% compared
with 2.7% (z = 1.1; p = 0.28)). Average time from receiving
the leaflet to presentation for those with relevant symp-
toms was 8 days earlier in the cohort receiving the leaflet
than in the control group (where the start time was the
date of leaflet distribution to the comparable intervention
group) (57 days compared with 65 (t = − 2.4, p = 0.02)). It
was not possible to confirm a difference in survival func-
tions when both were compared across the 4 -week follow
up (Log Rank (Mantel-Cox) χ2 = 1.42, p = 0.23).
Strengths and limitations
This research demonstrates the potential of
record-based methods for evaluating outcomes of gen-
eral practice interventions. The methodology enabled
the testing of a simple intervention across five practices
with modest resources. Sources of bias that can affect
observational studies were excluded by randomising the
distribution of leaflets. Age and index of multiple
deprivation were compared between the cohorts, con-
firming broad similarities. Primary and secondary
Table 1 Participant’s baseline characteristics
Characteristicsa Intervention Control Difference
Median age yrs. (IQRb) 58 (49–69) 58 (49–68) z = 0.302, p = 0.76
Median IMD (IQR) 15.4 (11.96–22.98) 15.4 (11.96–22.98) z = − 0.444, p = 0.66
aLess than 5% of records used the recommended codes for ethnicity and therefore no statistical comparison of ethnicity was performed
bInter-Quartile Range
Fig. 1 CONSORT diagram of recruitment, randomisation and analysis of intervention and control groups
Campbell et al. BMC Public Health  (2018) 18:997 Page 4 of 7
outcomes were defined in advance with sample size
drawn from a separate study that aimed to estimate the
likely symptom frequency in general practice popula-
tions [16]. Data was extracted and compiled without ref-
erence to allocation to intervention or control groups.
As with all record-based studies, the coded items
available and extracted may not identify all relevant pa-
tients, although the effect of this is likely to be similar in
intervention and control groups. In this study, the rate
of symptom presentation based on electronic records
was considerably less than predicted from estimates
based on a questionnaire study [16] which had been
used for the a priori sample size calculation. This may
have been due to inflated symptom incidence due to sur-
vey self-selection bias: it is possible that the questions
relating to gynaecological cancer symptoms may have
been differentially answered by those having symptoms.
Conversely, there may be an under-reporting of symp-
toms by GPs on electronic patient records. Although the
relative risk observed was similar to that used in the
sample size calculation (observed RR = 1.11 compared to
estimated RR = 1.13), the observed incidence was ap-
proximately one-tenth of the previously published esti-
mate. The actual power of the study was therefore only
20% (α = 0.05) and our study cannot exclude an effect of
leaflet distribution on help seeking that could be of
importance.
Comparison with existing literature
Few trials of interventions directed towards early presen-
tation of patients with cancer-related symptoms exist,
though it is known that targeted public information leaf-
lets can increase awareness of cancer symptoms [10–12].
A bowel cancer screening study in which leaflets sent to
individual patients from practices increased participation
in bowel cancer screening programmes by 3–4% [13]
and a study investigating the impact of leaflets on pres-
entation of stroke symptoms delivered as part of a multi-
faceted campaign [14] are particularly relevant. However,
Table 2 Trial outcomes
Primary outcomes Intervention Control Difference (control-intervention)
Proportion presenting 231/7799 (3.0%) 207/7739 (2.7%) RR = 1.11, 95%CI 0.92–1.33; p = 0.28
Time to presentation, Mean, 95% CI 57.2 (53.4–62.0) 65.2 (60.3–70.1) 8 days; t = −2.42, p = 0.02
Secondary outcomes
Proportion referred 66/7799 (0.8%) 51/7739 (0.7%) RR = 1.28, 95%CI 0.89–1.85; p = 0.18
Time to referral Mean, 95% CI 57.1 (48.0–66.1) 67.7 (57.4–78.0) 10.6 days; t = −1.53, p = 0.13
Other
Cancers diagnoseda 2 1
aThe numbers of cancers diagnosed was not compared statistically due to the small numbers
Fig. 2 Survival functions for time to symptom presentation
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other trials of leaflets promoting colorectal cancer
screening have been less successful [21].
This study is one of the first to attempt to systematic-
ally quantify the impact of an educational leaflet on rates
of, and time to, presentation for potential gynaecological
cancer symptoms in primary care. A prior evaluation of
the leaflet used in this study demonstrated that its im-
pact on patients’ anxiety levels was negligible and
changes in anxiety did not influence patients’ intentions
to seek help [12]. Some evidence for increased rates of
presentation in the three weeks after receiving the leaflet
was found, but this was a non-significant trend. There
was, however, a difference in time to presentation, with
women in the intervention group presenting with symp-
toms just over a week faster than those in the control
group. Evidence which quantifies the specific effect of
delay to presentation to clinical outcome is lacking in
the current literature and the evidence for diagnostic
delay is confounded by large effects due to the type of
cancer and stage of diagnosis, amongst other factors
[2, 22]. However, given that the NHS has a target of
14 days from presentation at GP to specialist consult-
ation for suspected cancers, an additional delay of 8 days
is intuitively clinically important and is an important ef-
fect in the context of possible public health impact.
Implications for research and practice
The National Awareness and Early Diagnosis Initiative
(NAEDI) was launched in the United Kingdom as part
of a strategy to improve cancer outcomes. The key hy-
pothesis underpinning NAEDI was that delays lead to
cancer patients being diagnosed with more advanced
disease and thus experiencing poor 1-year and 5-year
survival rates. An investigative phase was followed by
piloting and then definitive regional, disease -focused
campaigns directed towards raising public awareness of
symptoms and signs of common cancers [23]. The
model adopted was typically focused on single
awareness-raising messages using posters and leaflet dis-
tribution in conjunction with social marketing through
radio and television. Campaigns have had variable out-
comes, with one campaign to promote early diagnosis of
lung cancer claiming some success [24], and mixed re-
sults from campaigns directed towards bowel cancer,
urological cancer and ovarian cancer [25–28].
Attempts have been made to evaluate process and out-
come, with urgent cancer referrals most often used as a
proxy outcome. Where effects have been noted it re-
mains difficult to be clear what impact the components
of different campaigns might have, and in particular the
value of local distribution of leaflets. Evidence that a
low-intensity intervention such as leaflet distribution
may decrease the patient interval for potential cancer
symptoms lends support to pursuing this type of
approach as part of a wider strategy for reducing the
time to cancer diagnosis. This study does not provide re-
liable estimates for the likely impact on GP consultations
or urgent referrals, but these could be derived in a larger
randomised trial or observational study.
Conclusions
This study is one of the first to attempt to systematically
quantify the impact of an educational leaflet on rates of,
and time to presentation for potential cancer symptoms in
primary care. There was some evidence for increased rates
of presentation in the three weeks after receiving the leaf-
let, but this was not statistically significant. There was a
significant difference in time to presentation, with women
in the intervention group presenting with symptoms just
over a week faster than those in the control group. The
evidence that this low-intensity intervention may decrease
time to presentation for potential cancer symptoms lends
support to pursuing this type of approach as part of a
wider strategy for reducing the time to cancer diagnosis.
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